Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Operating Expenses data on file, last reported at $13.4 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses rose 23.8% year-over-year to $13.4 million; the trailing twelve-month figure through Dec 2025 stood at $48.3 million (up 83.94% YoY), and the FY2025 full-year result was $41.8 million, up 85.7% from the prior year.
• Operating Expenses improved to $13.4 million in Q4 2025, from $9.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $15.3 million in Q1 2025 to a low of $3.5 million in Q1 2022.
• A 5-year average of $6.6 million and a median of $5.2 million in 2021 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses dropped 7.54% in 2022 and jumped 270.32% in 2025, its largest moves.
• Tracing BNTC's Operating Expenses over 5 years: stood at $4.9 million in 2021, then rose by 15.72% to $5.6 million in 2022, then gained by 23.17% to $6.9 million in 2023, then jumped by 55.98% to $10.8 million in 2024, then climbed by 23.8% to $13.4 million in 2025.
• Business Quant data shows BNTC's Operating Expenses at $13.4 million in Q4 2025, $9.8 million in Q3 2025, and $9.8 million in Q2 2025.